Yamanouchi Pharmaceuticals Report issue

Contributed to NME For profit Phase 3
Founded: Osaka Japan (1923)
Status: Acquired by Astellas (2005) → now Leo Pharma (2015)

Organization Overview

First Clinical Trial
2002
NCT00151567
First Marketed Drug
2004
solifenacin (vesicare)
First NDA Approval
2004
solifenacin (vesicare)
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Yamanouchi | YAMANOUCHI

Active Ingredients

Marketed Drugs (2)

hydrocortisone (solu-cortef)

solifenacin (vesicare) (2004 NDA)

Drugs in Phase 3 Trials (1)

tamsulosin (flomax) (1 trial)

Indications

Approved Indications


 

Urinary Bladder, Overactive

Experimental Indications (Clinical Trials, Phases 1-4)


 

Calculi (Phase 3)

Ureteral Calculi (Phase 3)

Ureterolithiasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1